News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Business
Peplin Limited In A Strong Position Despite Loss
August 8, 2006
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
Skin cancer therapeutics firm Peplin Ltd says it is in a strong position, with two anti-cancer drugs in the latter stages of development and $31 million in cash.
Twitter
LinkedIn
Facebook
Email
Print
Earnings
Australia
MORE ON THIS TOPIC
Podcast
Q1 earnings take off, Lilly strikes many deals, Regeneron notches historic approval, FDA raises questions
April 29, 2026
·
1 min read
·
Heather McKenzie
Insights
Biotech angels lean into deeper diligence and disciplined early bets
April 29, 2026
·
4 min read
·
Jennifer C. Smith-Parker
Mergers & acquisitions
AbbVie sinks talons into KRAS with right to buy Kestrel for up to $1.45B
April 28, 2026
·
1 min read
·
Annalee Armstrong
Layoff Tracker
Novartis cuts hit New Jersey again, affecting 60 employees
April 28, 2026
·
51 min read
·
BioSpace Editorial Staff
